WallStSmart

Equinix Inc (EQIX)vsLineage, Inc. Common Stock (LINE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinix Inc generates 73% more annual revenue ($9.26B vs $5.36B). EQIX leads profitability with a 14.6% profit margin vs -1.9%. EQIX earns a higher WallStSmart Score of 50/100 (C-).

EQIX

Buy

50

out of 100

Grade: C-

Growth: 6.7Profit: 6.5Value: 2.0Quality: 3.5
Piotroski: 3/9Altman Z: 0.55

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQIXSignificantly Overvalued (-45.0%)

Margin of Safety

-45.0%

Fair Value

$598.17

Current Price

$963.00

$364.83 premium

UndervaluedFair: $598.17Overvalued

Intrinsic value data unavailable for LINE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQIX3 strengths · Avg: 8.3/10
Market CapQuality
$94.62B9/10

Large-cap with strong market position

Operating MarginProfitability
21.5%8/10

Strong operational efficiency at 21.5%

EPS GrowthGrowth
22.9%8/10

Earnings expanding 22.9% YoY

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

EQIX4 concerns · Avg: 2.5/10
Debt/EquityHealth
1.613/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.342/10

Expensive relative to growth rate

P/E RatioValuation
69.9x2/10

Premium valuation, high expectations priced in

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EQIX

The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bear Case : EQIX

The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 69.9x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

EQIX profiles as a value stock while LINE is a turnaround play — different risk/reward profiles.

EQIX is growing revenue faster at 8.1% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - SPECIALTY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

EQIX scores higher overall (50/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinix Inc

REAL ESTATE · REIT - SPECIALTY · USA

Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.

Visit Website →

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

Want to dig deeper into these stocks?